Listen to this article

Johnson & Johnson announced Oct. 9 it completed the acquisition of V-Wave Ltd., a privately held company that develops treatment options for patients with heart failure.  

When the deal was announced in August, the New Brunswick-headquartered health care giant said it would purchase V-Wave for $600 million with the potential for additional milestone payments of up to approximately $1.1 billion. 

Established in 2009, V-Wave has offices in Israel and California. The company will now operate as part of Johnson & Johnson MedTech. 

The deal extends Johnson & Johnson MedTech‘s position in cardiovascular disease, the company noted. 

In a statement, Tim Schmid, executive vice president and worldwide chairman of Johnson & Johnson MedTech, officially welcomed the V-Wave team to the company. 

“V-Wave’s novel implantable device, the Ventura Interatrial Shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market,” Schmid added. 

Johnson & Johnson expects the transaction to dilute adjusted earnings per share by approximately $0.24 in 2024 and approximately $0.06 in 2025. The company said it will provide an update to its full-year 2024 financial outlook when it reports third quarter 2024 results Oct. 15. 

Acquisition spree

Johnson & Johnson has made several acquisitions in recent months, including: 

• Yellow Jersey Therapeutics for $1.25 billion in July 
• Proteologix Inc. for $850 million in June 
• Shockwave Medical for $13.1 billion in May